- CAR-T in haematological malignancies
- Ethics and consent in CAR-T
- T-Cell journey
- Management of CAR-T toxicities
Suitable for general haematology ward nurses, stem cell transplant/cellular therapy nurses and ICU Nurses.
Our goal is to fundamentally change the way people think about cancer treatment by pushing the boundaries of what is possible with cell therapy — using genetically modified immune cells to target tumours.
Visit the Kite Pharma website for more information.
This is a non-promotional website intended as an educational material for healthcare professionals and has been created and fully-funded by Kite, a Gilead company. General discussion around CAR T therapy may be mentioned as well as anonymised patient cases
Novartis is reimagining medicine to improve and extend people’s lives including those with various blood disorders. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need.
In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Since the launch of Novartis’ first haematology treatment in the UK over 50 years ago, the company has continued to drive the innovation behind some of the most important scientific advances in this area.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in research and development and is a leading sponsor of clinical trials, in the UK. For more information, please visit the Novartis website.
If you are interested in sponsoring this event please contact us via email.
Sign up to our education events mailing list to be kept up to date with this and future events